<DOC>
	<DOCNO>NCT02725606</DOCNO>
	<brief_summary>The purpose present trial evaluate safety , tolerability pharmacokinetics ( PK ) /pharmacodynamics ( PD ) single subcutaneous injection GW003 breast cancer patient . Moreover , efficacy assess preliminary .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetics/Pharmacodynamics GW003 Patients With Breast Cancer</brief_title>
	<detailed_description>This single-center , open-label , randomize , active-controlled phase I study evaluate tolerability pharmacokinetics/pharmacodynamics single subcutaneous injection GW003 breast cancer patients.GW003 recombinant human serum albumin/human granulocyte-colony stimulating factor ( I ) fusion protein .It long-acting G-CSF ( Granulocyte-Colony Stimulating Factor ) . In study , participant administer single dose GW003 . Every subject accept one dose . In addition tolerability safety , pharmacokinetics/pharmacodynamics , preliminary efficacy immunogenicity GW003 evaluate well .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Aged 18 year 70 year , female Patients histologicallyconfirmed breast cancer plan accept adjuvant chemotherapy ( epirubicin plus cyclophosphamide ) Have Eastern Cooperative Oncology Group ( ECOG ) performance status≤2 Have clinically significant impairment cardiac , liver kidney Adequate hematologic , hepatic renal function meet following requirement : 1 . Absolute neutrophil count ( ANC ) ≥1.5 x 10^9/L 2 . Blood platelet ( PLT ) ≥100 x 10^9/L 3 . Serum creatinine ( sCr ) ≤1.5 time upper limit normal ( ULN ) 4 . Total bilirubin ( TBIL ) ≤1.5×ULN 5 . Aspartate aminotransferase ( AST ) /serum glutamicoxaloacetic transaminase ( SGOT ) and/or alanine aminotransferase ( ALT ) /serum glutamic pyruvic transaminase ( SGPT ) ≤ 2.5 x ULN 6 . Hemoglobin ( Hb ) ＞9 g/dL 7 . Alkaline phosphatase ( ALP ) ≤1.5×ULN Expected comply protocol With urine human chorionic gonadotropin ( hCG ) negative Signed informed consent With acute infection With history bone marrow transplant and/or stem cell transplant With primary hematological disease , myelodysplastic syndrome , aplastic anemia , sickle cell anemia Received surgery within 3 week chemotherapy Received GCSF within 4 week involve study Females pregnant lactating Participated clinical trial time within 4 week screen Known allergy chemotherapy drug , recombinant human granulocytecolony stimulate factor rh ( rhGCSF ) biological product With cacoethic addiction drug abuse alcoholism With case suitable study judge investigator</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>GW003</keyword>
</DOC>